Business
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment associated with a 5-year survival rate from disease onset of 42.3%, representing a 2-fold improvement over historical benchmarksThe 5-year survival rate from disease onset reached 52.9% in a subset of ALS patients without prior complete loss of functionality, highlighting the importance
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HWD4Ql95BpT7YVARTBJFHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNQ--/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS","length":178,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Masitinib treatment associated with a 5-year survival rate from disease onset of 42.3%, representing a 2-fold improvement over historical benchmarks","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"The 5-year survival rate from disease onset reached 52.9% in a subset of ALS patients without prior complete loss of functionality, highlighting the importance of early intervention","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Among the long-term survivors (patients who reached the 5-year survival milestone from symptom onset), 49% maintained a satisfactory quality of life, without need for mechanical assistance, such as ventilation, gastrostomy, tracheostomy, or wheelchair dependence ","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"Median overall survival of 121 months observed in long-term masitinib-treated survivors compared to 42 months predicted for this cohort by the ENCALS model, resulting in a 79-month residual median survival gain ","length":210,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":801,"olType":false},{"type":"text","content":"Paris, April 20, 2026, 9pm CET","length":30,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) announced the publication of a new article on the preprint platform medRxiv, evaluating long-term amyotrophic lateral sclerosis (ALS) survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study. The article is titled ‘Evaluation of Long-Term Amyotrophic La...